TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: The aims of this study were to evaluate the efficacy of JNJ-165 in CML cells with or without p53 mutation in vitro and in vivo as a single agent and in combination with TKI and to confirm the mechanism of action of this potentially important drug in CML cells.